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Introduction
This is not the crystalloids versus colloids debate. The question 
is: Having decided that you need to give a colloid, which one do 
you give? Colloids are given to restore or increase intravascular 
volume, and in theatre, this is frequently in the context of 
ongoing loss in the form of bleeding. A detailed discussion of 
transfusion triggers is beyond the scope of this paper. However, in 
every context, strong consideration should be given to whether 
a blood or a blood product may be the most appropriate colloid 
as oxygen-carrying capacity is an important consideration in the 
developing brain. An informal survey of anaesthetic colleagues 
abroad indicates that most would reach for blood or a blood 
product once they had determined that sufficient crystalloid 
had been given, and would only possibly consider the use of a 
synthetic colloid in an older child. 
Research in this area in paediatric age groups is fraught with 
ethical and practical problems, and as a result, there is a paucity 
of high-quality comparative trials. Thus, we are forced to base 
our practice on a few, limited paediatric studies, extrapolation 
from adult studies, expert opinion and our understanding of the 
physiology of each age group.
Physiology
Neonates have relatively high haemoglobin levels, but this is 
predominantly haemoglobin F, which has a limited capacity to 
release oxygen at tissue level. Additionally, particularly in the first 
week of life, clotting factor levels may be inadequate.1 For these 
reasons, blood and blood products are frequently required when 
large fluid infusions are being given. 
Although the full number of adult nephrons is present at birth, 
the tubular length takes approximately six months to reach 
adult levels.2 Therefore, diluting and concentrating abilities 
are limited. Renal function is not completely developed, and 
sodium clearance, in particular, is limited, which may reflect in 
the impaired ability to handle a sodium load. Limited trials in 
premature infants comparing albumin (Na+ 145mmol/ℓ) with 
0.9% NaCl (Na+ 154mmol/ℓ) infusion have, however, not shown 
this to be significant.3 
Physiological anaemia is experienced at around 8-12 weeks in 
an infant. The haemoglobin dips to approximately 9-11 g/dl. 
This may happen as early as three weeks in the premature infant 
and can be more profound, dipping to 7-9 g/dl.4 While this is a 
physiological adaptation to postnatal life, it may leave the infant 
vulnerable to inadequate oxygen delivery in a situation of an 
acute, substantial increase in oxygen demand (surgical stress and 
infection). Renal function in this age group is approaching adult 
capacity, and the handling of sodium loads does not appear to 
be a problem.
With respect to haemoglobin levels, clotting capacity and renal 
function, children over the age of two years are not vastly different 
from adults. Their increased metabolic rates and propensity to 
vasodilation, owing partly to increased parasympathetic tone, 
may make their oxygen requirements and fluid responsiveness 
somewhat different to that of adults. This should be assessed 
clinically and using point-of-care monitoring, such as near-
infrared spectroscopy and responded to as appropriate, to 
maintain adequate tissue oxygen delivery.
Available colloids 
Available colloids for paediatric use in the South African context 
are classified as those manufactured from natural proteins 
(albumin, stabilised human serum and freeze-dried plasma) or as 
synthetic colloids (starches and gelatins). No trials comparing all 
these agents have been done and, in the paediatric age group, 
trials using colloids are largely limited to the colloid vs crystalloid 
variety. 
Natural protein colloids
Although it is one of the most expensive colloids, albumin 
remains popular with paediatricians throughout the world, 
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and is also widely used by anaesthetic communities in 
North America, Australia and New Zealand. It is prepared in 
concentrations of 5-20%, with 5% being osmotically equivalent 
to plasma, and concentrations greater than this are possibly 
indicated in situations of albumin deficit (nephrotic syndrome 
and cirrhosis). It is the least allergenic of the colloids, but also 
the most susceptible to migration into the extravascular space, 
with an increase in vascular permeability.5 The only clear 
contraindication to its use, extrapolated from the adult literature, 
would appear to be traumatic brain injury.6
A comparison of albumin versus starch in children aged three 
years and younger undergoing cardiopulmonary bypass showed 
an improved urine output with albumin.7 Priming a paediatric 
bypass circuit with crystalloid versus crystalloid plus albumin 
led to better fluid balances and less weight gain, but more 
transfusion in the albumin group.8
Fresh frozen plasma (FFP) is used by some practitioners as a 
colloid. It should be remembered that this is a blood product, 
and although the overall risks of blood transfusion remain low, 
FFP is among the least safe blood components to transfuse. 
Haemolysis due to anti-A or anti-B antibodies if transfused 
across blood types; immunological reactions, such as allergy and 
anaphylaxis; and transfusion-related acute lung injury are among 
the most concerning adverse reactions that may be precipitated. 
Viruses are not inactivated in the preparation process and may 
be transmitted.9 In addition, FFP is hypertonic, with a sodium 
concentration of 165 mmol/l10 and may cause hypernatraemia 
with injudicious use.
Stabilised human serum (SHS) is a 5% protein product, prepared 
by filtering and inactivating plasma. The albumin content 
is approximately 3.6%. The remaining proteins are largely 
immunoglobulins which have a higher molecular weight than 
albumin, thus potentially resulting in increased intravascular 
longevity. Viral inactivation is achieved by ultraviolet irradiation 
and heat. The electrolyte profile renders it slightly hypo-osmotic 
at 260 mOsm/kg. Its processing results in a cost substantially 
more than that of the synthetic colloids.
Hydroxyethyl starches
Hydroxyethyl starches (HES) are modified polysaccharides 
suspended in 0.9% NaCl, or more recently, a more iso-osmotic 
solution. Hydroxyethyl groups are substituted for hydroxyl groups 
to improve the stability of the molecule. The molecular weight, 
degree of molar substitution and the position of substitution 
(usually C2 or C6) affects the time that the molecule remains 
active intravascularly, as well as the side-effects experienced. 
The high molecular weight/molar subsistution HES solutions 
particularly tend to be associated with hypocoagulability owing to 
as yet poorly understood effects on factor VIII, the von Willebrand 
factor and platelets.11,12 This effect is reduced, but not eliminated, 
in the medium- and low-molecular-weight starches.13,14 Renal 
effects, also maximal in the higher-molecular-weight solutions, 
include tubular swelling and hyperviscosity of the urine, and 
may be linked to the amount of time that the molecule is active 
intravascularly.15 The higher the C2:C6 substitution ratio, the 
slower the breakdown of the product, resulting in a prolonged 
intravascular effect. The newer starches are low to medium 
molecular weight, with a high C2:C6 substitution ratio, which 
may account for their observed renal effects, particularly in 
critically ill patients. Tissue accumulation, leading to pruritus, 
is a prominent side-effect with high-molecular-weight/molar 
substitution starches, which, while seldom causing significant 
clinical impact, can be very troubling to the patient.16
It has been suggested in several studies on adult and paediatric 
patients that there is a possible increase in blood loss post-
cardiopulmonary bypass (CPB) when HES solutions are used, 
although this is not always accompanied by an increase in 
transfusion requirements.11,17-20 These findings in children are 
supported by an in vitro study on infant thromboelastograms 
that compared albumin, gelatin and HES fluid boluses. The study 
demonstrated a reduced maximum amplitude and α-angle with 
a 15 ml/kg HES bolus.19 It must be borne in mind that not all HES 
studies are equal, and the older studies were conducted using 
high- or medium-molecular-weight solutions known to have a 
greater effect on coagulation. That said, the evidence seems to 
point to the rationale that HES may not be the ideal colloid in 
neonates, infants and children after a CPB.
Studies on the use of starches in paediatric patients, particularly 
those who are critically ill and/or have renal dysfunction are 
lacking, but extrapolation from adult evidence21-23 suggests that 
it is prudent to avoid starches in these patients. In other patients 
particular attention must be paid to recommended maximum 
daily doses. 
Gelatins
Gelatins are polypeptides manufactured from the degradation 
of bovine collagen. Its molecular weight (30-35 kDa) is the lowest 
of all commercially available colloids, and results in its relatively 
reduced plasma oncotic effect. In fact, due to rapid glomerular 
filtration, enzymatic cleavage and transient passage into the 
interstitial space, the increase in blood volume seen with the 
infusion of gelatins is actually less than the volume infused.15 As 
a result, repeated infusions are required to maintain the effect. 
There is no prescribed limit to the amount of gelatin that may 
be infused. 
Although not as marked as that with the starches, there is 
some effect on coagulation,19,24,25 and caution is advised when 
considering the use of gelatins in patients with underlying 
bleeding tendencies, such as von Willebrand’s disease. Gelatin 
is the most allergenic of all the commercially available colloid 
solutions.26 
Paediatric gelatin studies are limited. It was noted in a Cochrane 
review of early volume expansion in preterm infants that 
there was an increased likelihood of necrotising enterocolitis 
developing with the use of gelatin or no treatment, compared 
with the use of FFP.27 Adult studies have suggested a possible 
implication for the worsening of a capillary leak with the use of 
gelatins, which may have implications for septic neonates.28,29
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Gelatins remain the least expensive commercially available 
colloid, are effective plasma volume replacers and aside from 
the increased hypersensitivity reactions, are not associated with 
clinically significant adverse effects.
What I do
I seldom use colloids in the neonate and infant, and tend to 
give blood and blood products once I have determined that I 
have given sufficient crystalloid. Barring the contraindications 
mentioned, if I choose to give a colloid, a naturally occurring 
protein colloid, such as SHS, is my choice for a neonate, and 
130/0.4 HES for an infant. 130/0.4 HES is my first choice in 
children requiring colloid fluids.
Conclusion
It should be remembered that fluids are only one aspect of 
a resuscitation strategy which should aim to correct deficits 
in circulating volumes and constituents. Intrinsic cardiac and 
microvascular function, as well as neurohumeral changes, 
should also be considered. Adjunctive therapies, such as 
catecholamines which augment cardiac contraction and venous 
return, should not be forgotten. There is a tendency by clinicians 
to view catecholamines as a last resort, forgetting that many 
of our anaesthetic agents cause vasodilation and myocardial 
depression which will be reversed at the end of anaesthesia. 
Clinicians should rather consider starting with a low-dose 
infusion and to resist the urge to give more fluid. It may be given 
peripherally for a short while, if necessary, and weaned at the 
end of the case.  
In the absence of an ideal colloid or conclusive evidence to 
support one or other available option, the clinician is forced 
to rely on personal and institutional experience, extrapolation 
from adult studies, the consideration of evidence from limited 
paediatric studies, and expert opinion, when deciding which 
colloid to administer. Cost may also influence clinical decision-
making. What is clear is that this choice may have significant 
clinical implications, and should be undertaken with the same 
degree of consideration as that given to a drug prescription.
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